Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (169) 169
science & technology (169) 169
humans (159) 159
hematology (99) 99
oncology (96) 96
male (95) 95
middle aged (92) 92
female (91) 91
aged (83) 83
adult (72) 72
antineoplastic combined chemotherapy protocols - therapeutic use (66) 66
aged, 80 and over (56) 56
treatment outcome (56) 56
rituximab (48) 48
abridged index medicus (36) 36
hemic and lymphatic diseases (33) 33
lymphomas (32) 32
disease-free survival (31) 31
antineoplastic agents - therapeutic use (29) 29
prognosis (29) 29
vincristine - administration & dosage (27) 27
cancer (26) 26
care and treatment (26) 26
doxorubicin - administration & dosage (26) 26
lymphoma (26) 26
biological and medical sciences (25) 25
chemotherapy (25) 25
cyclophosphamide - administration & dosage (25) 25
medical sciences (25) 25
hematologic and hematopoietic diseases (23) 23
prednisone - administration & dosage (23) 23
antineoplastic combined chemotherapy protocols - administration & dosage (22) 22
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (22) 22
lymphoma, mantle-cell - drug therapy (22) 22
survival rate (21) 21
mantle cell lymphoma (20) 20
young adult (20) 20
antibodies, monoclonal, murine-derived - administration & dosage (19) 19
immune system diseases (19) 19
antibodies, monoclonal, murine-derived - therapeutic use (18) 18
lymphoma, large b-cell, diffuse - drug therapy (18) 18
neoplasm staging (18) 18
adolescent (17) 17
bortezomib (17) 17
clinical trials as topic (17) 17
immunotherapy (17) 17
doxorubicin - therapeutic use (16) 16
lymphoma, follicular - drug therapy (16) 16
lymphoma, mantle-cell - pathology (16) 16
lymphoma, mantle-cell - therapy (16) 16
recurrence (16) 16
research (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
clinical trials (15) 15
follow-up studies (15) 15
lymphoma, non-hodgkin - drug therapy (15) 15
survival analysis (15) 15
analysis (14) 14
antineoplastic agents - adverse effects (14) 14
bendamustine (14) 14
non-hodgkin lymphoma (14) 14
patients (14) 14
vincristine - therapeutic use (14) 14
antibodies, monoclonal - therapeutic use (13) 13
cyclophosphamide - therapeutic use (13) 13
prednisone - therapeutic use (13) 13
antineoplastic agents - administration & dosage (12) 12
drug therapy (12) 12
follicular lymphoma (12) 12
hodgkin disease - drug therapy (12) 12
kaplan-meier estimate (12) 12
drug administration schedule (11) 11
etoposide - administration & dosage (11) 11
lymphoma, mantle-cell - mortality (11) 11
remission induction (11) 11
survival (11) 11
transplantation (11) 11
antibodies, monoclonal, murine-derived - adverse effects (10) 10
antineoplastic agents (10) 10
clinical trials and observations (10) 10
combined modality therapy (10) 10
dose-response relationship, drug (10) 10
doxorubicin - adverse effects (10) 10
hematology, oncology and palliative medicine (10) 10
lymphoma, follicular - therapy (10) 10
non-hodgkin's lymphomas (10) 10
original reports (10) 10
risk factors (10) 10
tumors (10) 10
vincristine - adverse effects (10) 10
bendamustine hydrochloride (9) 9
bleomycin - administration & dosage (9) 9
disease progression (9) 9
hodgkin disease - pathology (9) 9
leukemia, lymphocytic, chronic, b-cell - drug therapy (9) 9
lymphoma, large b-cell, diffuse - mortality (9) 9
stem cells (9) 9
antibodies, monoclonal, murine-derived (8) 8
cyclophosphamide - adverse effects (8) 8
dacarbazine - administration & dosage (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Indolent lymphomas
by Kahl, Brad
Best practice & research. Clinical haematology, ISSN 1521-6926, 03/2018, Volume 31, Issue 1, pp. 1 - 1
Lymphoma - metabolism | Lymphoma - genetics | Lymphoma - diagnosis | Lymphoma - therapy | Humans | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text An iatrogenic orphan?
by Kahl, Brad S
Blood, ISSN 0006-4971, 10/2019, Volume 134, Issue 16, pp. 1273 - 1274
Life Sciences & Biomedicine | Hematology | Science & Technology | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Drug Approval | Rare Diseases | Iatrogenic Disease | Humans | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Follicular lymphoma: evolving therapeutic strategies
by Kahl, Brad S and Yang, David T
Blood, ISSN 0006-4971, 04/2016, Volume 127, Issue 17, pp. 2055 - 2063
Life Sciences & Biomedicine | Hematology | Science & Technology | Translocation, Genetic | Lymphoma, Follicular - drug therapy | Prognosis | Humans | Neoplasm Proteins - physiology | Transcriptome | Tumor Microenvironment | Molecular Targeted Therapy | Lymphoma, Follicular - epidemiology | Lymphoma, Follicular - genetics | Neoplasm Proteins - genetics | B-Lymphocyte Subsets - pathology | Lymphoma, Follicular - pathology | Selection, Genetic | V(D)J Recombination | Treatment Outcome | Genes, bcl-2 | Tumor Burden | Randomized Controlled Trials as Topic | Rituximab - administration & dosage | B-Lymphocyte Subsets - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Models, Biological | Disease Management | Immunologic Factors - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
by Wang, Michael L and Rule, Simon and Martin, Peter and Goy, Andre and Auer, Rebecca and Kahl, Brad S and Jurczak, Wojciech and Advani, Ranjana H and Romaguera, Jorge E and Williams, Michael E and Barrientos, Jacqueline C and Chmielowska, Ewa and Radford, John and Stilgenbauer, Stephan and Dreyling, Martin and Jedrzejczak, Wieslaw Wiktor and Johnson, Peter and Spurgeon, Stephen E and Li, Lei and Zhang, Liang and Newberry, Kate and Ou, Zhishuo and Cheng, Nancy and Fang, Bingliang and McGreivy, Jesse and Clow, Fong and Buggy, Joseph J and Chang, Betty Y and Beaupre, Darrin M and Kunkel, Lori A and Blum, Kristie A
The New England journal of medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 6, pp. 507 - 516
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Recurrence | Pyrazoles - therapeutic use | Administration, Oral | Humans | Middle Aged | Lymphoma, Mantle-Cell - drug therapy | Drug Resistance, Neoplasm | Male | Protein Kinase Inhibitors - adverse effects | Lymphoma, Mantle-Cell - mortality | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Pyrimidines - adverse effects | Survival Analysis | Aged, 80 and over | Lymphocyte Count | Adult | Female | Aged | Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - adverse effects | Antimitotic agents | Relapse | Lymphomas | Product development | Drug therapy | Antineoplastic agents | Cancer | Tyrosine | Thrombocytopenia | Bortezomib | Statistical analysis | Diarrhea | Fatigue | Nausea | Non-Hodgkin's lymphoma | Bruton's tyrosine kinase | Patients | Lymphoma | Signal transduction | Lymphocytes B | Antitumor activity | Protein-tyrosine kinase | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text BV for HL: Can the responses last?
by Kahl, Brad S
Blood, ISSN 0006-4971, 09/2016, Volume 128, Issue 12, pp. 1540 - 1541
Life Sciences & Biomedicine | Hematology | Science & Technology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Mantle cell lymphoma: The promise of new treatment options
by Goy, Andre and Kahl, Brad
Critical reviews in oncology/hematology, ISSN 1040-8428, 2010, Volume 80, Issue 1, pp. 69 - 86
Hematology, Oncology and Palliative Medicine | Bortezomib | Flavopiridol | Bendamustine | Lenalidomide | Mantle cell lymphoma | Rituximab | Temsirolimus | Non-Hodgkin's lymphoma | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Recurrence | Prognosis | Humans | Lymphoma, Mantle-Cell - drug therapy | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Enzyme Inhibitors - therapeutic use | Lymphoma, Mantle-Cell - mortality | Lymphoma, Mantle-Cell - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Angiogenesis Inhibitors - therapeutic use | Care and treatment | Biological products | Non-Hodgkin's lymphomas | Radiotherapy | Immunotherapy | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
by Roberts, Andrew W and Davids, Matthew S and Pagel, John M and Kahl, Brad S and Puvvada, Soham D and Gerecitano, John F and Kipps, Thomas J and Anderson, Mary Ann and Brown, Jennifer R and Gressick, Lori and Wong, Shekman and Dunbar, Martin and Zhu, Ming and Desai, Monali B and Cerri, Elisa and Heitner Enschede, Sari and Humerickhouse, Rod A and Wierda, William G and Seymour, John F
The New England journal of medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma
by Kahl, Brad S and Kahl, Brad S
Clinical advances in hematology & oncology, ISSN 1543-0790, 11/2018, Volume 16, Issue 11, pp. 732 - 734
Journal Article
Details down arrow
9. Full Text Targeting BCL-2 in Hematologic Malignancies
by Khan, Nadia and Kahl, Brad
Targeted oncology, ISSN 1776-2596, 6/2018, Volume 13, Issue 3, pp. 257 - 267
Biomedicine, general | Medicine & Public Health | Oncology | Life Sciences & Biomedicine | Science & Technology | Proteins | Medical colleges | Chemotherapy | Leukemia | Lymphomas | Drug approval | Cancer | Targeted cancer therapy | Lymphoma | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
by Gopal, Ajay K and Kahl, Brad S and de Vos, Sven and Wagner-Johnston, Nina D and Schuster, Stephen J and Jurczak, Wojciech J and Flinn, Ian W and Flowers, Christopher R and Martin, Peter and Viardot, Andreas and Blum, Kristie A and Goy, Andre H and Davies, Andrew J and Zinzani, Pier Luigi and Dreyling, Martin and Johnson, Dave and Miller, Langdon L and Holes, Leanne and Li, Daniel and Dansey, Roger D and Godfrey, Wayne R and Salles, Gilles A
The New England journal of medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 11, pp. 1008 - 1018
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Recurrence | Lymph Nodes - pathology | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Class Ia Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Disease-Free Survival | Neoplasm Grading | Antineoplastic Agents - adverse effects | Aged, 80 and over | Lymphocyte Count | Adult | Female | Aged | Lymphoma, Non-Hodgkin - mortality | Purines - adverse effects | Purines - therapeutic use | Quinazolinones - therapeutic use | Quinazolinones - adverse effects | Lymphoma, Non-Hodgkin - drug therapy | Phosphatidylinositol | Care and treatment | Lymphomas | Research | Medical research | Cell survival | Diarrhea | Rituximab | B-cell receptor | Non-Hodgkin's lymphoma | Kinases | Patients | Lymphoma | 1-Phosphatidylinositol 3-kinase | Chemotherapy | Lymphocytes B | Antitumor activity | Neutropenia | Macroglobulinemia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Evolving treatment strategies in mantle cell lymphoma
by Edwin, Natasha Catherine and Kahl, Brad
Best practice & research. Clinical haematology, ISSN 1521-6926, 09/2018, Volume 31, Issue 3, pp. 270 - 278
Clinical trials | Novel therapeutics | Mantle cell lymphoma | Life Sciences & Biomedicine | Hematology | Science & Technology | Bendamustine Hydrochloride - therapeutic use | Autografts | Cytarabine - therapeutic use | Humans | Lymphoma, Mantle-Cell - pathology | Neoplasm, Residual | Stem Cell Transplantation | Rituximab - therapeutic use | Lymphoma, Mantle-Cell - therapy | Maintenance Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Mantle-Cell - blood | Anthracyclines - therapeutic use | Medical colleges | Medical research | Chemotherapy | Anthracyclines | Comorbidity | Stem cells | Medicine, Experimental | Transplantation | Lymphomas | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights